TY - STD TI - Toyoda H, Atsukawa M, Takaguchi K, Senoh T, Michitaka K, Hiraoka A, et al. Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan. J Gastroenterol. 2018. https://doi.org/10.1007/s00535-018-1473-z. ID - ref1 ER - TY - JOUR AU - Okubo, T. AU - Atsukawa, M. AU - Tsubota, A. AU - Toyoda, H. AU - Shimada, N. AU - Abe, H. PY - 2018 DA - 2018// TI - Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment JO - Hepatol Int VL - 12 UR - https://doi.org/10.1007/s12072-018-9859-9 DO - 10.1007/s12072-018-9859-9 ID - Okubo2018 ER - TY - JOUR AU - Pol, S. AU - Jadoul, M. AU - Vallet-Pichard, A. PY - 2017 DA - 2017// TI - An update on the management of hepatitis C virus-infected patients with stage 4-5 chronic kidney disease while awaiting the revised KDIGO guidelines JO - Nephrol Dial Transplant VL - 32 ID - Pol2017 ER - TY - JOUR AU - Arai, T. AU - Atsukawa, M. AU - Tsubota, A. AU - Ikegami, T. AU - Shimada, N. AU - Kato, K. PY - 2018 DA - 2018// TI - Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease JO - Hepatol Res VL - 48 UR - https://doi.org/10.1111/hepr.13058 DO - 10.1111/hepr.13058 ID - Arai2018 ER - TY - JOUR AU - Alseiari, M. AU - Meyer, K. B. AU - Wong, J. B. PY - 2016 DA - 2016// TI - Evidence underlying KDIGO (kidney disease: improving global outcomes) guideline recommendations: a systematic review JO - Am J Kidney Dis VL - 67 UR - https://doi.org/10.1053/j.ajkd.2015.09.016 DO - 10.1053/j.ajkd.2015.09.016 ID - Alseiari2016 ER - TY - JOUR AU - Uojima, H. AU - Kobayashi, S. AU - Hidaka, H. AU - Shuichi, M. AU - Takayasu, O. AU - Takeshi, K. PY - 2017 DA - 2017// TI - Virological response to daclatasvir and asunaprevir combination therapy for chronic hepatitis C virus genotype 1b infection in dialysis patients: a prospective, multicenter study JO - Ren Replace Ther VL - 3 UR - https://doi.org/10.1186/s41100-016-0091-6 DO - 10.1186/s41100-016-0091-6 ID - Uojima2017 ER - TY - JOUR AU - Morisawa, N. AU - Koshima, Y. AU - Kuriyama, S. AU - Matsuyama, M. AU - Hayashi, N. AU - Satoh, J. I. PY - 2017 DA - 2017// TI - Effectiveness of a fixed combination formula of ombitasvir/paritaprevir/ritonavir for hepatitis C virus infection in patients on maintenance haemodialysis JO - Nephrology VL - 22 UR - https://doi.org/10.1111/nep.13011 DO - 10.1111/nep.13011 ID - Morisawa2017 ER - TY - JOUR AU - Maunoury, F. AU - Clément, A. AU - Nwankwo, C. AU - Levy-Bachelot, L. AU - Abergel, A. AU - Martino, V. PY - 2018 DA - 2018// TI - Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France JO - PLoS One VL - 13 UR - https://doi.org/10.1371/journal.pone.0194329 DO - 10.1371/journal.pone.0194329 ID - Maunoury2018 ER - TY - JOUR AU - Kosloski, M. P. AU - Zhao, W. AU - Marbury, T. C. AU - Preston, R. A. AU - Collins, M. G. AU - Pugatch, D. PY - 2018 DA - 2018// TI - Effects of renal impairment and hemodialysis on the pharmacokinetics and safety of the glecaprevir and pibrentasvir combination in hepatitis C virus-negative subjects JO - Antimicrob Agents Chemother VL - 62 ID - Kosloski2018 ER - TY - JOUR AU - Krishnan, P. AU - Schnell, G. AU - Tripathi, R. AU - Beyer, J. AU - Reisch, T. AU - Dekhtyar, T. PY - 2018 DA - 2018// TI - Integrated resistance analysis of CERTAIN-1 and CERTAIN-2 studies in hepatitis C virus-infected patients receiving glecaprevir and pibrentasvir in Japan JO - Antimicrob Agents Chemother VL - 62 UR - https://doi.org/10.1128/AAC.01249-18 DO - 10.1128/AAC.01249-18 ID - Krishnan2018 ER - TY - JOUR AU - Poordad, F. AU - Pol, S. AU - Asatryan, A. AU - Buti, M. AU - Shaw, D. AU - Hézode, C. PY - 2018 DA - 2018// TI - Glecaprevir/pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure JO - Hepatology VL - 67 UR - https://doi.org/10.1002/hep.29671 DO - 10.1002/hep.29671 ID - Poordad2018 ER - TY - JOUR AU - Gane, E. AU - Lawitz, E. AU - Pugatch, D. AU - Papatheodoridis, G. AU - Bräu, N. AU - Brown, A. PY - 2017 DA - 2017// TI - Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1704053 DO - 10.1056/NEJMoa1704053 ID - Gane2017 ER - TY - JOUR AU - Uchida, Y. AU - Kouyama, J. AU - Naiki, K. AU - Mochida, S. PY - 2014 DA - 2014// TI - A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors JO - PLoS One VL - 9 UR - https://doi.org/10.1371/journal.pone.0112647 DO - 10.1371/journal.pone.0112647 ID - Uchida2014 ER - TY - JOUR AU - Fabrizi, F. AU - Takkouche, B. AU - Lunghi, G. AU - Dixit, V. AU - Messa, P. AU - Martin, P. PY - 2007 DA - 2007// TI - The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies JO - J Viral Hepat VL - 14 ID - Fabrizi2007 ER - TY - JOUR AU - Söderholm, J. AU - Millbourn, C. AU - Büsch, K. AU - Kövamees, J. AU - Schvarcz, R. AU - Lindahl, K. PY - 2018 DA - 2018// TI - Higher risk of renal disease in chronic hepatitis C patients: antiviral therapy survival benefit in patients on hemodialysis JO - J Hepatol VL - 68 UR - https://doi.org/10.1016/j.jhep.2017.12.003 DO - 10.1016/j.jhep.2017.12.003 ID - Söderholm2018 ER - TY - JOUR AU - Atsukawa, M. AU - Chayama, K. AU - Suzuki, F. AU - Sato, K. AU - Karino, Y. AU - Atarashi, T. PY - 2017 DA - 2017// TI - Efficacy and safety of glecaprevir/pibrentasvir in patients infected with HCV GT1 - 3 by renal impairment status: a pooled analysis of two phase 3 Japanese trials JO - Hepatology VL - 66 ID - Atsukawa2017 ER - TY - JOUR AU - Ozer Etik, D. AU - Ocal, S. AU - Boyacioglu, A. S. PY - 2015 DA - 2015// TI - Hepatitis C infection in hemodialysis patients: a review JO - World J Hepatol VL - 7 UR - https://doi.org/10.4254/wjh.v7.i6.885 DO - 10.4254/wjh.v7.i6.885 ID - Ozer Etik2015 ER - TY - JOUR AU - Abad, S. AU - Vega, A. AU - Hernández, E. AU - Mérida, E. AU - Sequera, P. AU - Albalate, M. PY - 2017 DA - 2017// TI - Universal sustained viral response to the combination of ombitasvir/paritaprevir/ritonavir and dasabuvir with/without ribavirin in patients on hemodialysis infected with hepatitis C virus genotypes 1 and 4 JO - Am J Nephrol VL - 45 UR - https://doi.org/10.1159/000454819 DO - 10.1159/000454819 ID - Abad2017 ER - TY - JOUR AU - Liu, C. H. AU - Liu, C. J. AU - Huang, C. F. AU - Lin, J. W. AU - Dai, C. Y. AU - Liang, C. C. PY - 2015 DA - 2015// TI - Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial JO - Gut VL - 64 UR - https://doi.org/10.1136/gutjnl-2014-307080 DO - 10.1136/gutjnl-2014-307080 ID - Liu2015 ER - TY - JOUR AU - Franczyk-Skóra, B. AU - Gluba-Brzózka, A. AU - Wranicz, J. K. AU - Banach, M. AU - Olszewski, R. AU - Rysz, J. PY - 2015 DA - 2015// TI - Sudden cardiac death in CKD patients JO - Int Urol Nephrol VL - 47 UR - https://doi.org/10.1007/s11255-015-0994-0 DO - 10.1007/s11255-015-0994-0 ID - Franczyk-Skóra2015 ER - TY - JOUR AU - Pockros, P. J. AU - Reddy, K. R. AU - Mantry, P. S. AU - Cohen, E. AU - Bennett, M. AU - Sulkowski, M. S. PY - 2016 DA - 2016// TI - Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease JO - Gastroenterology VL - 150 UR - https://doi.org/10.1053/j.gastro.2016.02.078 DO - 10.1053/j.gastro.2016.02.078 ID - Pockros2016 ER - TY - JOUR AU - Puoti, M. AU - Foster, G. R. AU - Wang, S. AU - Mutimer, D. AU - Gane, E. AU - Moreno, C. PY - 2018 DA - 2018// TI - High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: an integrated analysis of HCV genotype 1-6 patients without cirrhosis JO - J Hepatol VL - 69 UR - https://doi.org/10.1016/j.jhep.2018.03.007 DO - 10.1016/j.jhep.2018.03.007 ID - Puoti2018 ER - TY - JOUR AU - Gane, E. AU - Poordad, F. AU - Wang, S. AU - Asatryan, A. AU - Kwo, P. Y. AU - Lalezari, J. PY - 2016 DA - 2016// TI - High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis JO - Gastroenterology VL - 151 UR - https://doi.org/10.1053/j.gastro.2016.07.020 DO - 10.1053/j.gastro.2016.07.020 ID - Gane2016 ER - TY - JOUR AU - Peres, L. A. B. AU - Passarini, S. R. AU - Branco, M. F. B. T. AU - Kruger, L. A. PY - 2014 DA - 2014// TI - Skin lesions in chronic renal dialysis JO - J Bras Nefrol VL - 36 UR - https://doi.org/10.5935/0101-2800.20140008 DO - 10.5935/0101-2800.20140008 ID - Peres2014 ER -